Evidence map›Paper›PMID 25864879›Full record

ArticleChemistry, an Asian journal2015

Study of the Function of G-Rich Aptamers Selected for Lung Adenocarcinoma.

Jun Hu, Zilong Zhao, Qiaoling Liu, Mao Ye, Bingqiang Hu, Jing Wang, Weihong Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry, an Asian journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Antiproliferative Effects of the Aptamer d(GGGT)International journal of molecular sciences · 2022
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jun HuMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, and Collaborative Research Center of Molecular, Engineering for Theranostics, Hunan University, Changsha, 410082, P.R. China.
Zilong ZhaoMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, and Collaborative Research Center of Molecular, Engineering for Theranostics, Hunan University, Changsha, 410082, P.R. China.
Qiaoling LiuMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, and Collaborative Research Center of Molecular, Engineering for Theranostics, Hunan University, Changsha, 410082, P.R. China.
Mao YeMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, and Collaborative Research Center of Molecular, Engineering for Theranostics, Hunan University, Changsha, 410082, P.R. China.
Bingqiang HuHunan Tumor Hospital, Changsha, 410013, P.R. China.
Jing WangHunan Tumor Hospital, Changsha, 410013, P.R. China.
Weihong TanMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, and Collaborative Research Center of Molecular, Engineering for Theranostics, Hunan University, Changsha, 410082, P.R. China. tan@chem.ufl.edu.
Hunan University · CNHunan Cancer Hospital · CNInterface (United States) · US

Funding

Development of molecular probes for biomedical applicationsR01GM079359 · NIGMS · UNIVERSITY OF FLORIDA · PI TAN, WEIHONG · 2007 to 2016
$2.3M
Molecular Target for Liver Cancer Diagnosis and TherapyR01CA133086 · NCI · UNIVERSITY OF FLORIDA · PI LIU, CHEN · 2009 to 2013
$1.5M
NCI NIH HHS CA133086NIGMS NIH HHS GM079359NIGMS NIH HHS R01 GM079359
6 · The paper itself

Abstract

Guanine (G)-rich oligonucleotides have attracted considerable interest as therapeutic agents. Two G-rich aptamers were selected against epidermal growth factor receptor (EGFR)-transfected A549 cells, and their G-rich domains (S13 and S50) were identified to account for the binding of parental aptamers. Circular dichroism (CD) spectra showed that S13 and S50 bound to their targets by forming parallel quadruplexes. Their binding, internalization, and antiproliferation activity in cancer and noncancer cells were investigated by flow cytometry and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay, and compared with those of nucleolin-binding AS1411 and thrombin-binding aptamer. The two truncated aptamers (S13 and S50) have good binding and internalization in cancer cells and noncancer cells; however, only S50, similar to AS1411, shows potent antiproliferation against cancer cells. Our data suggest that tumor-selective antiproliferation of G-rich oligonucleotides does not directly depend on the binding of the G-rich aptamer to cells.

Indexed as

G-QuadruplexesAdenocarcinomaAdenocarcinoma of LungAntineoplastic AgentsAptamers, NucleotideBase SequenceCell Line, TumorCell ProliferationErbB ReceptorsHumansLungLung NeoplasmsMolecular Sequence DataNucleolinOligodeoxyribonucleotidesPhosphoproteinsAGRO 100Antineoplastic AgentsAptamers, NucleotideEGFR protein, humanErbB ReceptorsNucleolinOligodeoxyribonucleotidesPhosphoproteinsRNA-Binding Proteinsthrombin aptamerantiproliferationaptamerscancercell recognitionG-quadruplexes

Identifiers

PMID25864879
PMCPMC4966285
OpenAlexW2120614229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.